Real-World Semaglutide Use Improves Diabetes Control in Chinese Adults

Globally, Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by high blood sugar, leading to severe complications like cardiovascular disease and kidney failure. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have emerged as highly effective treatments, demonstrating significant improvements in glycemic control and weight loss in controlled clinical trials. However, there remains a critical need to understand their effectiveness and safety in diverse, everyday clinical practice settings, especially in specific regional populations; this study addresses the knowledge gap regarding semaglutide's real-world efficacy and safety among adults with T2D in Tianjin, China.

The study revealed significant improvements across multiple metabolic parameters in patients treated with semaglutide. After 12 months, the mean HbA1c level decreased by 1.5% from a baseline of 8.2% to 6.7% (p<0.001), with 65% of patients achieving an HbA1c target of <7.0%. Patients experienced a mean body weight reduction of 7.8 kg (p<0.001), representing a 9.1% decrease from baseline. Systolic blood pressure also saw a mean reduction of 5.2 mmHg (p<0.01). > The most impactful finding was the 2.3-fold increase in the proportion of patients achieving both HbA1c <7.0% and >5% weight loss compared to baseline, demonstrating comprehensive metabolic improvement. Furthermore, the incidence of severe adverse events was low, consistent with previous clinical trial data.